Previous 10 | Next 10 |
Biotech company Invitae’s (NVTA) substantial revenue growth in its last reported quarter, and its progress in ushering personalized health monitoring into the mainstream, have impressed investors. However, the company’s top-line growth is not expected to translate into profitabi...
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories. Ms. Stueland joins GeneDx f...
Invitae (NVTA) appoints Roxi Wen as its chief financial officer, effective June 21, 2021. She is a CFA charterholder and has an MBA from the University of Minnesota.Roxi Wen comes to Invitae from Mozilla Corporation, where she served as CFO for the past two years. Prior to Mozilla, Wen s...
Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer PR Newswire SAN FRANCISCO , June 11, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief fi...
Shares of Invitae (NYSE: NVTA) fell 17.5% in May, according to data provided by S&P Global Market Intelligence . Investors were not impressed with the company's first-quarter earnings early in the month, especially management's inability to control costs. The reaction ma...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nowadays, medicine is being tailored to individual patients — even to their DNA. Known as “precision medicine,” this trend first kicked off in earnest only a few years ago. It’s a true game cha...
Invitae Corporation (NVTA) William Blair 41st Annual Growth Stock Conference June 03, 2021 4:20 PM ET Company Participants Sean George - CEO, Invitae Corporation Conference Call Participants Brian Weinstein - William Blair Presentation Brian Weinstein Good afternoon. My name is Brian Weinstei...
Invitae opens early access to liquid biopsy-based Personalized Cancer Monitoring as a central laboratory service -- Provides monitoring for recurrence of cancer based on each person's tumor-specific genetic information -- PR Newswire SAN FRANCISCO , June 3, 202...
Invitae is among the companies pioneering genomics. The company is building a platform that can use DNA to drive smarter healthcare decision-making throughout various life stages. However, the company continues to aggressively burn cash. The company has had many equity raises that hav...
Well, probably not all the chips, but taking home most of them is certainly possible. Cathie Wood of ARK investment Management has described Invitae (NYSE: NVTA) as operating in a "winner-take-most" market, and identified Invitae as one of the most under-appreciated companies in her...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...